[1][10][11][12] A phase III trial was completed in April 2016[13] and had it been approved it would have competed with AstraZeneca's Tagrisso (osimertinib).

[14] In September 2018, the company and two former executives agreed to a $20 million settlement with the Securities and Exchange Commission on claims it exaggerated to investors the efficacy of Roci in patient trials.

[15][16] Rucaparib is a PARP inhibitor in Phase II and III clinical trials for advanced ovarian cancer.

[17] In December 2016, the Food and Drug Administration granted an accelerated approval for the use of rucaparib "for the treatment of patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer who have been treated with two or more chemotherapies".

[18] In 2023, rucaparib was sold to Pharmaand GmbH (Pharma&) as part of Clovis's bankruptcy proceedings.